A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: Trans Tech Pharmaceuticals

Criteria

Inclusion Criteria:

• Diagnosis of probably Alzheimer's disease for at least 1 year.

• Mini Mental State Exam (MMSE) score between 12-26 at screening.

• Participants must be receiving a cholinesterase inhibitor and/or memantine for at least 4 months, and on a stable dose for at least 2 months.

Exclusion Criteria:

• Current evidence of a neurological or psychiatric illness that could contribute to dementia.

• Living alone.

• Poorly controlled high blood pressure.